Breast Cancer

University of Alabama to initiate phase I trial of HER-2 vaccine

Published in Women's Health Weekly, December 19th, 2002

Galenica Pharmaceuticals announced that the University of Alabama at Birmingham Comprehensive Cancer Center (UAB-CCC) is beginning a National Cancer Institute-sponsored phase I human clinical trial of a HER-2 vaccine containing Galenica's immune enhancer GPI-0100.

The trial will evaluate a therapeutic vaccine containing a HER-2 derived antigen designed by UAB and Ohio State University scientists together with Galenica's proprietary immune enhancer GPI-0100 to treat patients with HER-2 overexpressing cancers.

Preclinical studies showed that vaccination with this antigen, a synthetic peptide containing regions of the HER-2 receptor and the measles...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2002-12-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry